Kadouh H, Chedid V, Halawi H, et al
Understanding the cardiovascular profile of GLP-1 agonists is essential for both prescribers and patients, particularly given the metabolic conditions they are used to treat often carry inherent cardiovascular risk
Takviye biimindeki olanlar sv ve kapsl-tablet formlarnda alnabilir
Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women with non-classic congenital adrenal hyperplasia (NCAH)
Ancak genellikle dzenli kullanmda 2-4 hafta iinde ciltte parlaklk, enerji art ve genel salkta iyileme gibi etkiler grlmeye balanr
Strategies to enhance the tolerability of GLP-1-based therapy might include identification of agents that stimulate release of endogenous GLP-1 from intestinal L-cells, potentially accompanied by fewer adverse effects